Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses

Molecular Cancer Therapeutics

Volumn 5, Issue 3, 2006, Pages 755-766

  Komarova, Svetlana ^a   Kawakami, Yosuke ^a   Stoff Khalili, Mariam A ^a,b   Curiel, David T ^a   Pereboeva, Larisa ^a  

^a University of Alabama at Birmingham   (United States)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR;

ADENOVIRUS VECTOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; COCULTURE; CONTROLLED STUDY; FEMALE; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; ONCOLYTIC VIRUS; OVARY CARCINOMA; PRIORITY JOURNAL; TUMOR CELL DESTRUCTION; VIRAL GENE THERAPY; VIRION; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; COCULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED STRAINS; ONCOLYTIC VIRUSES; OVARIAN NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33645468259     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0334     Document Type: Article

References (51)

1. Ries SJ, Brandts CH. Oncolytic viruses for the treatment of cancer: current strategies and clinical trials. Drug Discov Today 2004;9:759-68.
2. Vile R, Ando D, Kirn D. The oncolytic virotherapy treatment platform for cancer: unique biological and biosafety points to consider. Cancer Gene Ther 2002;9:1062-7.
3. Krasnykh V, Dmitriev I, Navarro JG, et al. Advanced generation adenoviral vectors possess augmented gene transfer efficiency based upon coxsackie adenovirus receptor-independent cellular entry capacity. Cancer Res 2000;60:6784-7.
4. Korokhov N, Mikheeva G, Krendelshchikov A, et al. Targeting of adenovirus via genetic modification of the viral capsid combined with a protein bridge. J Virol 2003;77:12931-40.
5. Everts M, Curiel DT. Transductional targeting of adenoviral cancer gene therapy. Curr Gene Ther 2004;4:337-46.
6. Croyle MA, Chirmule N, Zhang Y, Wilson JM. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum Gene Ther 2002;13:1887-900.
7. Denby L, Work LM, Graham D, et al. Adenoviral serotype 5 vectors pseudotyped with fibers from subgroup D show modified tropism in vitro and in vivo. Hum Gene Ther 2004;15:1054-64.
8. Shayakhmetov DM, Li ZY, Ni S, Lieber A. Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J Virol 2004;78:5368-81.
9. Schiedner G, Hertel S, Johnston M, et al. Selective depletion or blockade of Kupffer cells leads to enhanced and prolonged hepatic transgene expression using high-capacity adenoviral vectors. Mol Ther 2003;7:35-43.
10. O'Riordan CR, Song A, Lanciotti J. Strategies to adapt adenoviral vectors for targeted delivery. Methods Mol Med 2003;76:89-112.
11. Kreppel F, Gackowski J, Schmidt E, Kochanek S. Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors. Mol Ther 2005;12:107-17.
12. Lanciotti J, Song A, Doukas J, et al. Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates. Mol Ther 2003;8:99-107.
13. Alemany R, Curiel DT. CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther 2001;8: 1347-53.
14. Huard J, Lochmuller H, Acsadi G, et al. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther 1995;2:107-15.
15. v integrin-binding ablation fails to reduce Ad5 liver tropism. Mol Ther 2003;8: 485-94.
16. Pereboeva L, Curiel DT. Cellular vehicles for cancer gene therapy: current status and future potential. BioDrugs 2004;18:361-85.
17. Rochlitz CF, Jantscheff P, Bongartz G, et al. Gene therapy with cytokine-transfected xenogeneic cells in metastatic tumors. Adv Exp Med Biol 1998;451:531-7.
18. Streit M, Stephen AE, Hawighorst T, et al. Systemic inhibition of tumor growth and angiogenesis by thrombospondin-2 using cell-based antiangiogenic gene therapy. Cancer Res 2002;62:2004-12.
19. Namba H, Tagawa M, Miyagawa T, Iwadate Y, Sakiyama S. Treatment of rat experimental brain tumors by herpes simplex virus thymidine kinase gene-transduced allogeneic tumor cells and ganciclovir. Cancer Gene Ther 2000;7:947-53.
20. Chester J, Ruchatz A, Gough M, et al. Tumor antigen-specific induction of transcriptionally targeted retroviral vectors from chimeric immune receptor-modified T cells. Nat Biotechnol 2002;20:256-63.
21. Raykov Z, Balboni G, Aprahamian M, Rommelaere J. Carrier cell-mediated delivery of oncolytic parvoviruses for targeting metastases. Int J Cancer 2004;109:742-9.
22. Pereboeva L, Komarova S, Mikheeva G, Krasnykh V, Curiel DT. Approaches to utilize mesenchymal progenitor cells as cellular vehicles. Stem Cells 2003;21:389-404.
23. Studeny M, Marini FC, Champlin RE, et al. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-β delivery into tumors. Cancer Res 2002;62:3603-8.
24. Studeny M, Marini FC, Dembinski JL, et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 2004;96:1593-603.
25. Krasnykh VN, Mikheeva GV, Douglas JT, Curiel DT. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol 1996;70:6839-46.
26. Dmitriev I, Krasnykh V, Miller CR, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998;72:9706-13.
27. Suzuki K, Alemany R, Yamamoto M, Curiel DT. The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses. Clin Cancer Res 2002;8:3348-59.
28. Davydova J, Le LP, Gavrikova T, et al. Infectivity-enhanced cyclooxygenase-2-based conditionally replicative adenoviruses for esophageal adenocarcinoma treatment. Cancer Res 2004;64:4319-27.
29. Suzuki K, Fueyo J, Krasnykh V, et al. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res 2001;7:120-6.
30. Fueyo J, Gomez-Manzano C, Alemany R, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000;19:2-12.
31. Wu JC, Sundaresan G, Iyer M, Gambhir SS. Noninvasive optical imaging of firefly luciferase reporter gene expression in skeletal muscles of living mice. Mol Ther 2001;4:297-306.
32. Allers C, Sierralta WD, Neubauer S, et al. Dynamic of distribution of human bone marrow-derived mesenchymal stem cells after transplantation into adult unconditioned mice. Transplantation 2004;78:503-8.
33. Conget PA, Minguell JJ. Adenoviral-mediated gene transfer into ex vivo expanded human bone marrow mesenchymal progenitor cells. Exp Hematol 2000;28:382-90.
34. Bianco P, Riminucci M, Gronthos S, Robey PG. Bone marrow stromal stem cells: nature, biology, and potential applications. Stem Cells 2001; 19:180-92.
35. Kanerva A, Wang M, Bauerschmitz GJ, et al. Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther 2002;5:695-704.
36. Kanerva A, Mikheeva GV, Krasnykh V, et al. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 2002;8:275-80.
37. Bauerschmitz GJ, Lam JT, Kanerva A, et al. Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res 2002; 62:1266-70.
38. Ram Z, Culver KW, Oshiro EM, et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 1997;3:1354-61.
39. Ram Z, Culver KW, Walbridge S, et al. Toxicity studies of retroviral-mediated gene transfer for the treatment of brain tumors. J Neurosurg 1993;79:400-7.
40. Li S, Tokuyama T, Yamamoto J, et al. Bystander effect-mediated gene therapy of gliomas using genetically engineered neural stem cells. Cancer Gene Ther 2005;12:600-7.
41. Namba H, Tagawa M, Iwadate Y, et al. Bystander effect-mediated therapy of experimental brain tumor by genetically engineered tumor cells. Hum Gene Ther 1998;9:5-11.
42. Crittenden M, Gough M, Chester J, et al. Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapy. Cancer Res 2003;63:3173-80.
43. Yotnda P, Savoldo B, Charlet-Berguerand N, Rooney C, Brenner M. Targeted delivery of adenoviral vectors by cytotoxic T cells. Blood 2004; 104:2272-80.
44. Jevremovic D, Gulati R, Hennig I, et al. Use of blood outgrowth endothelial cells as virus-producing vectors for gene delivery to tumors. Am J Physiol Heart Circ Physiol 2004;287:H494-500.
45. Nakamizo A, Marini F, Amano T, et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005; 65:3307-18.
46. Nakamura K, Ito Y, Kawano Y, et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 2004;11:1155-64.
47. Sato H, Kuwashima N, Sakaida T, et al. Epidermal growth factor receptor-transfected bone marrow stromal cells exhibit enhanced migratory response and therapeutic potential against murine brain tumors. Cancer Gene Ther 2005;12:757-68.
48. Vaillancourt MT, Atencio I, Quijano E, Howe JA, Ramachandra M. Inefficient killing of quiescent human epithelial cells by replicating adenoviruses: potential implications for their use as oncolytic agents. Cancer Gene Ther 2005;12:691-8.
49. Herrlinger U, Woiciechowski C, Sena-Esteves M, et al. Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas. Mol Ther 2000;1:347-57.
50. Gossen M, Freundlieb S, Bender G, et al. Transcriptional activation by tetracyclines in mammalian cells. Science 1995;268:1766-9.
51. Coukos G, Makrigiannakis A, Kang EH, et al. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clin Cancer Res 1999;5:1523-37.